Last reviewed 2026-04-22 · How we verify

Olmesartan medoxomil tablets low dose

Olmesartan medoxomil tablets low dose is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. It is currently FDA-approved for Hypertension.

Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.

Olmesartan medoxomil tablets (low dose) is an angiotensin II receptor blocker (ARB) marketed by Daiichi Sankyo Europe for hypertension management. The drug selectively blocks the AT1 angiotensin II receptor, preventing vasoconstriction and reducing blood pressure through a well-established mechanism. Approved across Europe and other markets, olmesartan is indicated for essential hypertension as monotherapy or in combination with other antihypertensive agents. Clinical evidence demonstrates efficacy in reducing systolic and diastolic blood pressure, with particular benefit in patients with metabolic syndrome and cardiovascular risk factors. The low-dose formulation provides flexible dosing for treatment initiation and titration, competing in the mature ARB market alongside losartan, valsartan, and irbesartan. Commercial significance is moderate within the broader antihypertensive class, with generic competition present in most markets post-patent expiry.

At a glance

Mechanism of action

Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, an angiotensin II receptor blocker (ARB). It selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues, blocking the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced peripheral vascular resistance, and decreased blood pressure.

Approved indications

• Hypertension

Common side effects

• Dizziness
• Hyperkalemia
• Renal impairment
• Cough
• Fatigue

Key clinical trials

• Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
• Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Olmesartan medoxomil tablets low dose CI brief — competitive landscape report
• Olmesartan medoxomil tablets low dose updates RSS · CI watch RSS
• Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company portfolio CI

Frequently asked questions about Olmesartan medoxomil tablets low dose

Related

• Drug class: All Angiotensin II receptor blocker (ARB) drugs
• Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
• Manufacturer: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Hypertension
• Compare: Olmesartan medoxomil tablets low dose vs similar drugs
• Pricing: Olmesartan medoxomil tablets low dose cost, discount & access